GTBP
Price:
$0.6299
Market Cap:
$6.69M
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies fo...[Read more]
Industry
Biotechnology
IPO Date
2018-03-27
Stock Exchange
NASDAQ
Ticker
GTBP
According to GT Biopharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -715.46%. This represents a change of -1814.89% compared to the average of 41.72% of the last 4 quarters.
The mean historical ROE of GT Biopharma, Inc. over the last ten years is -177.06%. The current -715.46% ROE has changed 304.09% with respect to the historical average. Over the past ten years (40 quarters), GTBP's ROE was at its highest in in the December 2024 quarter at 226.05%. The ROE was at its lowest in in the September 2018 quarter at -1748.87%.
Average
-177.06%
Median
-54.66%
Minimum
-2246.17%
Maximum
788.14%
Discovering the peaks and valleys of GT Biopharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.82%
Maximum Annual ROE = 788.14%
Minimum Annual Increase = -875.59%
Minimum Annual ROE = -2246.17%
| Year | ROE | Change |
|---|---|---|
| 2024 | 788.14% | -875.59% |
| 2023 | -101.62% | -42.90% |
| 2022 | -177.98% | -32.78% |
| 2021 | -264.78% | -373.84% |
| 2020 | 96.69% | -52.11% |
| 2019 | 201.91% | -108.99% |
| 2018 | -2246.17% | 3.82% |
| 2017 | -57.24% | 9.91% |
| 2016 | -52.08% | -222.31% |
| 2015 | 42.58% | -46.69% |
The current ROE of GT Biopharma, Inc. (GTBP) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
169.52%
5-year avg
68.09%
10-year avg
-177.06%
GT Biopharma, Inc.’s ROE is greater than Artelo Biosciences, Inc. (-496.36%), less than Protagenic Therapeutics, Inc. (336.39%), less than Carisma Therapeutics, Inc. (162.29%), greater than Salarius Pharmaceuticals, Inc. (-401.03%), greater than Windtree Therapeutics, Inc. (-602.06%), less than Psyence Biomedical Ltd. (2.41%), less than Silexion Therapeutics Ltd. (1.22%), greater than Lipella Pharmaceuticals Inc. (-685.24%), greater than Dermata Therapeutics, Inc. (-191.97%), greater than Revelation Biosciences, Inc. (-194.47%),
| Company | ROE | Market cap |
|---|---|---|
| -496.36% | $4.00M | |
| 336.39% | $3.32M | |
| 162.29% | $2.28M | |
| -401.03% | $5.30M | |
| -602.06% | $2.02M | |
| 2.41% | $1.29M | |
| 1.22% | $1.73M | |
| -685.24% | $1.43M | |
| -191.97% | $1.74M | |
| -194.47% | $5.93M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GT Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GT Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is GT Biopharma, Inc.'s ROE?
How is the ROE calculated for GT Biopharma, Inc. (GTBP)?
What is the highest ROE for GT Biopharma, Inc. (GTBP)?
What is the 3-year average ROE for GT Biopharma, Inc. (GTBP)?
What is the 5-year average ROE for GT Biopharma, Inc. (GTBP)?
How does the current ROE for GT Biopharma, Inc. (GTBP) compare to its historical average?